Table 3 Summary of CAR-NK cell clinical trials
Type of malignancy | CAR-NK Cell product | Phase stage | Status | Last update posted | Identifier |
|---|---|---|---|---|---|
B-cell NHL, ALL, CLL, WM | Allogeneic CAR-NK cells targeting CD19 | Phase 1 | Recruiting | November 17, 2021 | NCT05020678 |
Multiple myeloma | Anti-BCMA CAR-NK Cells | Early Phase 1 | Recruiting | November 23, 2021 | NCT05008536 |
AML/MDS | Allogeneic CAR-NK targeting NKG2D | Phase 1 | Recruiting | May 17, 2021 | NCT04623944 |
AML | anti-CD33 CAR-NK cells | Phase 1 | Not yet recruiting | August 17, 2021 | NCT05008575 |
B-cell NHL, ALL, CLL | CAR-NK-CD19 Cells | Phase 1 | Recruiting | April 8, 2021 | NCT04796675 |
Hematological malignancy | CD5 CAR-engineered IL15-transduced cord blood-derived NK cells | Phase 1 Phase 2 | Not yet recruiting | November 8, 2021 | NCT05110742 |
B-cell Lymphoma, ALL, CLL | CAR-NK-CD19 Cells | Phase 1 | Recruiting | March 15, 2021 | NCT04796688 |
Multiple Myeloma | BCMA CAR-NK 92 cells | Phase 1 Phase 2 | Recruiting | May 7, 2019 | NCT03940833 |
NHL | Anti-CD19 CAR-NK | Early Phase 1 | Not yet recruiting | November 20, 2020 | NCT04639739 |
B-cell NHL | Anti-CD19 CAR-NK | Phase 1 | Recruiting | May 14, 2021 | NCT04887012 |
B-Cell lymphoma, MDS, AML | CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells | Phase 1 Phase 2 | Not yet recruiting | November 2, 2021 | NCT05092451 |
B-cell NHL | CD19 CAR-NK cell therapy (TAK-007) | Phase 2 | Not yet recruiting | November 11, 2021 | NCT05020015 |
Malignant tumor | ROBO1 BiCAR-NK/T-cells | Phase 1 Phase 2 | Recruiting | April 30, 2019 | NCT03931720 |
Glioblastoma | HER2-specific, CAR-expressing NK-92 cells (NK-92/5.28. z) | Phase 1 | Recruiting | September 25, 2020 | NCT03383978 |
Prostate cancer | Anti-PSMA CAR-NK cells | Phase 1 Phase 2 | Not yet recruiting | October 2, 2018 | NCT03692663 |
Gastroesophageal junction cancers, Advanced HNSCC | PD-L1 CAR-NK Cells | Phase 2 | Recruiting | November 23, 2021 | NCT04847466 |
Pancreatic cancer | ROBO1 CAR-NK cells | Phase 1 Phase 2 | Recruiting | May 8, 2019 | NCT03941457 |
Solid tumors | ROBO1 CAR-NK cells | Phase 1 Phase 2 | Recruiting | May 7, 2019 | NCT03940820 |